Investigational drug · Phase 2
RRx-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Oral Mucositis.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
14
Any phase or sponsor naming "RRx-001"
First trial start
2024
Apr 2, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RRx-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Oral Mucositis
Largest trials
Live from ClinicalTrials.gov: studies naming "RRx-001" as an intervention, largest first.
- A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung CancerPivotal-lookingStatus unknown
EpicentRx, Inc.Industry
NCT05566041 · 292 participants (planned) · Start Aug 1, 2022 · Primary completion Dec 31, 2025
Drug: RRx-001 + eLOOP Device; Cisplatin/carboplatin plus etoposide · For: Carcinoma, Small Cell Lung
Sites: Tampa, Florida; Westwood, Kansas
- RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck CancerPivotal-lookingActive, not recruiting
EpicentRx, Inc.Industry
NCT05966194 · 216 participants (planned) · Start Apr 2, 2024 · Primary completion Jul 1, 2027
Drug: RRx-001; Cisplatin for injection 100 mg/m2 · For: Oral Mucositis
Sites: Gilbert, Arizona; Tucson, Arizona; Miami, Florida · 14 sites in all
- RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)Pivotal-lookingCompleted
EpicentRx, Inc.Industry
NCT02489903 · 139 participants · Start Jun 2015 · Primary completion Dec 6, 2021
Drug: RRx-001; Cisplatin and 10 more · For: Small Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Neuroendocrine Tumors and 1 more
Sites: Palo Alto, California; West Haven, Connecticut; South Bend, Indiana · 10 sites in all
EpicentRx, Inc.Industry
NCT02096354 · 62 participants · Start May 2014 · Primary completion Apr 13, 2018
Drug: RRx-001; Regorafenib and 1 more · For: Colorectal Neoplasms
Sites: La Jolla, California; Stanford, California; Honolulu, Hawaii · 5 sites in all
EpicentRx, Inc.Industry
NCT03515538 · 53 participants · Start Jul 12, 2018 · Primary completion Oct 22, 2019
Drug: RRx-001; Cisplatin for injection · For: Oral Mucositis
Sites: Santa Monica, California; Denver, Colorado; Washington D.C., District of Columbia · 12 sites in all
EpicentRx, Inc.Industry
NCT02215512 · 29 participants · Start Feb 6, 2015 · Primary completion Nov 28, 2016
Drug: RRx-001 + WBRT · For: Brain Metastases
Sites: Santa Monica, California; Ann Arbor, Michigan; Jackson, Michigan · 5 sites in all
EpicentRx, Inc.Industry
NCT02801097 · 28 participants · Start Aug 30, 2016 · Primary completion Nov 22, 2018
Drug: RRx-001; Irinotecan · For: Malignant Solid Tumor; Metastatic Cancer; Advanced Cancer
Sites: Sacramento, California; New Brunswick, New Jersey
EpicentRx, Inc.Industry
NCT01359982 · 26 participants · Start Sep 2011 · Primary completion Feb 2015
Drug: RRx-001; RRx-001 and 4 more · For: Malignant Solid Tumor; Lymphomas
Sites: La Jolla, California; Nashville, Tennessee
EpicentRx, Inc.Industry
NCT02871843 · 19 participants · Start Feb 14, 2017 · Primary completion Oct 11, 2019
Drug: RRx-001 dose escalation with TMZ + RT; Fixed dose Temozolomide (75 mg/m2) and 1 more · For: Glioblastoma; Oligodendroglioma; Anaplastic Oligodendroglioma
Sites: San Francisco, California; New Brunswick, New Jersey; New York, New York
- RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung CancerPivotal-lookingTerminated
EpicentRx, Inc.Industry
NCT03699956 · 18 participants · Start Dec 24, 2018 · Primary completion Aug 11, 2022
Drug: Cisplatin/carboplatin plus etoposide · For: Carcinoma, Small Cell Lung
Sites: Denver, Colorado; Orange City, Florida; Orlando, Florida · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Modulation of G6PD-mediated Vitamin C Sensitivity in Small Cell Lung Cancer by the AKT/NRF2 axis.
Yao X, Lyu Y, Zhang Z, et al. · J Biol Chem 2026
- RRx-001 induces apoptosis through reactive oxygen species and endoplasmic reticulum stress in Burkitt lymphoma cells by acting as CD47 and c-Myc regulator.
Xu L, Lu T, Deng L, et al. · Biochim Biophys Acta Mol Basis Dis 2026
- RRx-001 sensitizes triple-negative breast cancer cells to oxaliplatin through apoptosis, cell cycle arrest, and immune modulation.
Al-Fatlawi RK, Al-Khfajy WS · J Pharmacol Exp Ther 2026
- A multidimensional pan-cancer analysis of CD47 and its role in promoting malignant phenotype in pancreatic adenocarcinoma.
Su S, Wu B, Li Y, et al. · Clin Transl Oncol 2026
- Coupling oxidative de-stabilization with immune activation overcomes radioresistance in hepatocellular carcinoma.
Liu J, Mi Z, Tan H, et al. · Mol Cancer 2026
- Size-Transformable Supramolecular Nanoprodrugs Enable Redox Imbalance Amplification and Cholesterol Modulation to Boost Multidimensional Tumor Immunotherapy.
Zhang Q, Meng L, Wang Z, et al. · Small 2026
Also in development for Oral Mucositis
- MIT-001Phase 21 trial
MitoImmune Therapeutics · Head and Neck Squamous Cell Carcinoma, Oral Mucositis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.